Pacific Biosciences of California, Inc. is engaged in the development, manufacture, and marketing of an integrated platform for high resolution genetic analysis. The company has developed a technology to study the synthesis, composition, structure, and regulation of deoxyribonucleic acid (DNA). The company created a technology platform using its proprietary single molecule, real-time (SMRT) technology. The SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The ability to observe single molecule events in real time provides the scientific community with an advanced tool for investigating basic biochemical processes such as DNA synthesis. Products The company focuses on offering SMRT technology to the DNA sequencing market where it has developed a third generation sequencing platform, the PacBio RS II sequencing system. The PacBio RS II The PacBio RS II is an instrument that uses proprietary consumables, including SMRT Cells and reagent kits that are used to prepare and sequence DNA samples. The PacBio RS II instrument conducts, monitors and analyzes biochemical sequencing reactions. The instrument is an integrated unit that includes high performance optics, automated liquid handling, a touchscreen control interface, a computational blade center and software. The instrument’s touchscreen control interface, the RS Touch, is the user’s primary control center to design and monitor experiments as they occur in real time. The blade center is the computational brain of the PacBio RS II, responsible for processing the sequencing data being produced on the SMRT Cells. The PacBio RS II has been designed to allow for performance improvements without replacement of the instrument hardware. Consumables To run PacBio RS II, customers have to purchase proprietary consumable products. The company’s consumable products include proprietary SMRT Cells and reagent kits. One SMRT Cell is consumed per sequencing reaction on the PacBio RS II. The company offers various reagent kits, each designed to address a specific step in the workflow. The Template Preparation Kit is used to convert DNA into SMRTbell double-stranded DNA library format and therefore includes typical molecular biology reagents, such as ligase, buffers and exonucleases. Product Enhancements In 2013, the company introduced a software upgrade which included a highly enabling method for de novo genome assembly called HGAP and a consensus algorithm called Quiver. Together, these software tools simplified the process for users to analyze data generated by their PacBio instruments and to assemble highly accurate genomes using only standard, PacBio long reads. The company also introduced the PacBio RS II system and RS to RS II upgrade kit, which effectively doubled the throughput of the original PacBio RS; P5 polymerase and C3 chemistry combination (P5-C3), which enables customers to generate sequences with read lengths averaging approximately 8,500 bases, with the longest read lengths exceeding 40,000 bases. In addition, the company has partnered with F. Hoffman- La Roche Ltd. (Roche) to explore and develop SMRT technology-based products for diagnostic applications. Intellectual Property As of December 31, 2013, the company owned exclusive licenses to 134 issued U.S. patents, 114 pending U.S. patent applications, 65 granted foreign patents and 107 pending foreign patent applications, including foreign counterparts of U.S. patent and patent applications. The full term of the issued U.S. patents would expire between 2016 and 2032. Research and Development The company’s research and development expenses included $45.2 million during 2013. Markets and Customers The company’s customers use products for sequencing the genomes of a range of organisms. The PacBio RS II is suited for sequencing small and medium size genomes, such as bacteria and fungi, and for sequencing targeted regions of larger genomes such as humans and plants. The company sells products to customers outside the United States, including customers in other areas of North America, Europe, and Asia. The company’s customers include genome centers, clinical, government and academic institutions, genomics service providers, pharmaceutical companies and agricultural companies. Competition The company’s competitors include Illumina Inc. and Thermo Fisher Scientific Inc. History Pacific Biosciences of California, Inc., formerly Nanofluidics, Inc. was incorporated in the state of Delaware in 2000.
pacific biosciences of calif
1380 Willow Road
Menlo Park, CA 94025
|Enzo Biochem Inc||$4.57 USD||+0.06|
|Fluidigm Corp||$33.14 USD||+0.83|
|Luminex Corp||$18.99 USD||+0.39|
|NanoString Technologies Inc||$14.48 USD||+0.55|
|Sequenom Inc||$3.73 USD||+0.14|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PACIFIC BIOSCIENCES OF CALIF, please visit www.pacificbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.